High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)
Gane, E., Poordad, F., Asatryan, A., Lalezari, J., Hassanein, T., Aguilar, H., Ng, T.I., Liu, Ran, Lin, C.-W., Kort, J., Mensa, F.Volume:
64
Year:
2016
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/s0168-8278(16)01475-6
File:
PDF, 51 KB
english, 2016